Schmitz EMH, et al. - This multicentre observational prospective cohort study was performed to examine the switch from infliximab innovator to biosimilar in an inflammatory bowel disease (IBD) cohort with 12 months follow-up to assess safety and effectiveness. In this IBD cohort, no differences were found in drug levels and disease activity between infliximab innovator and biosimilar, indicating that biosimilars were safe and effective. Findings revealed that the high proportions of discontinuers were mostly because of elective withdrawal or subjective disease worsening.